Compare IOVA & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | MFA |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 881.3M | 976.0M |
| IPO Year | N/A | N/A |
| Metric | IOVA | MFA |
|---|---|---|
| Price | $2.60 | $9.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | $10.45 | ★ $10.96 |
| AVG Volume (30 Days) | ★ 12.8M | 1.6M |
| Earning Date | 02-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | ★ 14.94% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.86 |
| Revenue | $250,425,000.00 | ★ $279,011,000.00 |
| Revenue This Year | $60.71 | N/A |
| Revenue Next Year | $59.52 | N/A |
| P/E Ratio | ★ N/A | $11.21 |
| Revenue Growth | ★ 175.62 | N/A |
| 52 Week Low | $1.64 | $7.85 |
| 52 Week High | $6.36 | $11.08 |
| Indicator | IOVA | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 44.26 |
| Support Level | $2.21 | $9.81 |
| Resistance Level | $3.03 | $10.19 |
| Average True Range (ATR) | 0.20 | 0.22 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 48.78 | 9.16 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.